1 March 2020 in Lung Cancer
Stage I non-small cell lung cancer (NSCLC) can be treated with either Stereotactic Body Radiotherapy (SBRT) or Video Assisted Thoracic Surgery (VATS) resection. To support decision making, not only the impact on survival needs to be taken into account, but also on quality of life, costs and cost-effectiveness. Therefore, we performed a cost-effectiveness analysis comparing SBRT to VATS resection with respect to quality adjusted life years (QALY) lived and costs in operable stage I NSCLC. Patient level and aggregate data from eight Dutch databases were used to estimate costs, health utilities, recurrence free and overall survival. Propensity score matching was used to minimize selection bias in these studies. A microsimulation model predicting lifetime outcomes after treatment in stage I NSCLC patients was used for the cost-effectiveness analysis. Model outcomes for the two treatments were overall survival, QALYs, and total costs. We used a Dutch health care perspective with 1.5 % discounting for health effects, and 4 % discounting for costs, using 2018 cost data. The impact of model parameter uncertainty was assessed with deterministic and probabilistic sensitivity analyses. Patients receiving either VATS resection or SBRT were estimated to live 5.81 and 5.86 discounted QALYs, respectively. Average discounted lifetime costs in the VATS group were €29,269 versus €21,175 for SBRT. Difference in 90-day excess mortality between SBRT and VATS resection was the main driver for the difference in QALYs. SBRT was dominant in at least 74 % of the probabilistic simulations. Using a microsimulation model to combine available evidence on survival, costs, and health utilities in a cost-effectiveness analysis for stage I NSCLC led to the conclusion that SBRT dominates VATS resection in the majority of simulations.
1 September 1993 in Clinical Neurology and Neurosurgery
1 June 2022 in Acta Oncologica
The recent POLDER trial investigated the effects of external beam radiotherapy (EBRT) on dysphagia caused by incurable oesophageal cancer. An estimated life expectancy of minimally three months was...
1 August 2007 in Journal of Thoracic Oncology
Background: In the era of targeted agents, combined chemoradiotherapy remains standard of care for non-resectable stage III non-small cell lung cancer (NSCLC). While recognizing that we have probably reached a plateau in terms of treatment results using this strategy, it is still imperative to reduce toxicities while not compromising efficacy. This study aims to evaluate a non-platinum-containing regimen used in conjunction with radiotherapy. Methods: Patients with histologically proven, non-resectable stage III NSCLC are eligible for the study. They must be above 18 years old, have good performance status, and have adequate bone marrow, renal and hepatic function. Patients will receive 2 cycles of induction vinorelbine (25mg/m 2) and gemcitabine (1000mg/m 2) given on days 1 and 8 every 21 days, followed by radiotherapy 60-66Gy with concurrent weekly vinorelbine (15mg/m 2). The primary objective is to assess the response rate to this regimen and secondary objectives to assess tolerability and toxicity. Results: We have completed the target accrual of 42 patients. There are 31 males and 11 females. The median age is 65, range of 41 to 79. Sixty-one percent has stage IIIB disease and 38.9% has stage IIIA disease. Forty-four percent of the patients have adenocarcinoma and 25% of patients have squamous cell carcinoma. Fifteen patients (36%) achieved a partial response after induction chemotherapy. After chemoradiotherapy, 7 patients had complete response and 19 patients had partial response, giving an overall response rate of 62%. Toxicity data is available for 36 patients. Nine patients(25%) had grade 3 or 4 neutropenia, 4 patients(11%) had grade 3 esophagitis and 3 patients(8%) had grade 3 fatigue. Conclusion: The toxicities of this regimen are low and the response rate is comparable to similar treatment schedules with platinum-based chemotherapy.